A 10-week, proof-of-concept study examining 12 CD patients receiving osilodrostat, reported no important changes in insulin levels, although a nearly significant decrease in HbA1c was noted ( 96 ).
1
—
—
A 10-week, proof-of-concept study examining 12 CD patients receiving osilodrostat, reported no important changes in insulin levels, although a nearly significant decrease in HbA1c was noted ( 96 ).